Analysts Set Intra-Cellular Therapies Inc (NASDAQ:ITCI) PT at $22.64
Intra-Cellular Therapies Inc (NASDAQ:ITCI) has been given a consensus recommendation of “Buy” by the ten ratings firms that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $22.64.
A number of equities analysts have recently weighed in on the company. JMP Securities set a $21.00 target price on Intra-Cellular Therapies and gave the stock a “buy” rating in a research note on Tuesday, September 10th. BidaskClub upgraded Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research note on Thursday, October 31st. Jefferies Financial Group a ...